Search the Newsreel

Vivos Therapeutics, Inc. (VVOS) Reports Q2 Loss, Lags Revenue Estimates

Vivos Therapeutics, Inc. (VVOS) reported a Q2 loss of $0.31 per share, which was better than the Zacks Consensus Estimate of a $0.42 loss. However, the company missed revenue estimates, posting $5.15 million against an expected $5.43 million. Despite beating EPS estimates two out …

Is Innoviva (INVA) A Bargain After Revenue Grew But Earnings Turned To Loss?

Wall Street Zen Upgrades Vivani Medical (NASDAQ:VANI) to "Hold"

Wall Street Zen has upgraded Vivani Medical (NASDAQ:VANI) from a "sell" to a "hold" rating, contributing to a consensus "Hold" rating with an average price target of $3.75. Analyst opinions are varied, with Lake Street Capital initiating coverage with a "buy" rating and a …

Vivani Medical (NASDAQ: VANI) Completes Full Enrollment In Semaglutide Implant Trial, Strikes Novo Nordisk Deal

Vivani Medical (NASDAQ: VANI) announced full enrollment in its SLIM-1 Phase 1 trial for NPM-139, a semaglutide implant, with top-line data expected in November 2026. The company also signed a non-exclusive agreement with Novo Nordisk for evaluating NPM-139 and its NanoPortal technology. Additionally, Vivani …

Vivakor | NT 10-Q: Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB

This article states that Vivakor has filed an NT 10-Q notice, indicating an inability to timely file all or part of a form 10-Q or 10-QSB. This notice is filed under Rule 12b25. The content explicitly states "Document," implying the document itself is the …

Israel Discount Bank (TASE:DSCT) Stock Grinds Higher As Margin Squeeze Lingers

Vivos Therapeutics Reports Q2 2026 Results: Full Earnings Call Transcript

Vivos Therapeutics reported a 35% increase in second-quarter revenue to $5.2 million, driven by service revenue from sleep testing and Vivos treatment, leading to an improved gross margin of 57%. The company is pursuing several growth initiatives, including remote patient monitoring for CPAP patients, …

Vivos Therapeutics Q2 revenue up 35% YoY; gross margin expands to 57%

Vivakor (VIVK) delays Q2 2026 10-Q but signals higher revenue and lower loss

Vivos Therapeutics, Inc. Q2 2026: Revenue $5.15M, EPS $(0.31) — 10-Q Summary

Vivos Therapeutics, Inc. reported its second-quarter 2026 financial results, showing revenue of $5.15 million, a 35% increase year-over-year. Despite the revenue growth, the company's net loss attributable to stockholders widened to $5.48 million, though diluted loss per share narrowed to $(0.31) due to an …

Vivos Therapeutics reports 35% revenue increase in Q2 2026 By Investing.com

Vivos Therapeutics Reports 35% Quarterly Revenue Growth, Rising Patient Demand and Second Quarter 2026 Results

Telefonica Brasil (NYSE:VIV) Sees Strong Trading Volume - Should You Buy?

VivoSim Labs (NASDAQ: VIVS) Emerges in Drug Toxicity Market as Revenue Growth Guidance Tops 500% – Plus More In Focus

Armistice Capital discloses 4.99% VVOS position in Vivos Therapeutics (VVOS)

Vivos Therapeutics schedules Q2 2026 results, conference call

Vivos Therapeutics Inc (NASDAQ: VVOS) is set to release its second quarter 2026 financial results after market close on August 14, 2026. Following the release, the company will host a conference call at 5:00 pm ET to discuss the results, provide operational updates, and …

Vivos to discuss collaborations’ anticipated effect on revenue growth and cash burn

Vivos Therapeutics (NASDAQ: VVOS) will release its second quarter 2026 financial results after market close on Friday, August 14, 2026, and will host a conference call at 5:00 p.m. Eastern Time. Management plans to discuss strategic collaborations and their anticipated effect on near-term revenue …

Aviva boss urges Chancellor to clamp down on pre-budget policy rumours

The boss of insurer Aviva has urged the new Chancellor not to "fly kites" with prospective policies ahead of the October budget after last year's speculation around pension changes. Chief executive Dame Amanda Blanc said widespread rumours that the Government might cut or restrict …

Viva Energy (ASX:VEA) Surges to Lead Gains Among Energy Stocks

Viva Biotech Sets Board Meeting to Approve Interim Results and Mull Dividend

Bank of America Corp DE Has $37.75 Million Stake in Innoviva, Inc. $INVA

Bank of America Corp DE increased its stake in Innoviva, Inc. (NASDAQ:INVA) by 6.6% in the first quarter, now owning 1,619,994 shares valued at approximately $37.75 million. Institutional investors and hedge funds collectively own 99.12% of Innoviva, and the stock currently has an average …

Aviva earnings jump by 24% amid swift progress on Direct Line turnaround

Insurer Aviva has seen half-year earnings surge by nearly a quarter as it cheered action to "quickly" improve profitability at Direct Line since buying the firm in a £3.7 billion deal. The group reported a better-than-expected 24% surge in operating profits to £1.33 billion …

Vivakor | 8-K: Current report

This document is an 8-K current report filed by Vivakor. The 8-K form is used by public companies to announce significant events that investors should know about. Without further content, the specific nature of this significant event is unknown.

Invivyd earnings missed by $0.03, revenue fell short of estimates

Invivyd (NASDAQ: IVVD) reported second-quarter EPS of $-0.140, missing analyst estimates by $0.03, and revenue of $14.29M, falling short of the $15.64M consensus. The company's stock price has declined by -43.310% over the last three months and -2.980% over the last twelve months. Despite …

Form 8K Vivakor Inc For: 13 August By Investing.com

This article reports on Vivakor Inc.'s Form 8K filing for August 13. The company, trading under the symbol VIVK, experienced a slight dip in its stock performance. The content primarily serves as a notice of the filing and a brief update on the stock's …

Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates

Invivyd, Inc. (IVVD) reported a Q2 loss of $0.14 per share, surpassing the Zacks Consensus Estimate of a $0.15 loss, but missed revenue estimates with $14.29 million against an expected $16.50 million. Despite the earnings beat, the company's shares have fallen significantly this year, …

Vivani Medical (NASDAQ:VANI) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Vivani Medical (NASDAQ:VANI) reported a quarterly loss of $0.07 per share, exceeding analyst estimates by $0.01. Despite beating expectations, shares fell 2.2% to $1.34. The company has an average "Hold" rating from analysts with a target price of $3.75, and director Gregg Williams recently …

Vivani Medical: Q2 Earnings Snapshot

Invivyd (IVVD) widens loss, warns on going concern as cash falls to $160M

Invivyd, Inc. (IVVD) reported a widened net loss of $85.8 million for the first half of 2026 and warned of substantial doubt about its ability to continue as a going concern, as its cash and cash equivalents fell to $160.1 million. The company's PEMGARDA …

Invivyd, Inc. Q2 2026: Revenue $14.29M, EPS $(0.14) — 10-Q Summary

Invivyd, Inc. reported its second-quarter 2026 results, showing a 21.2% year-over-year revenue increase to $14.29 million, driven by demand for PEMGARDA. Despite this, the company experienced a widened net loss of $(44.39) million, resulting in a diluted loss per share of $(0.14). Significant progress …

Vivani Medical (VANI) widens GLP‑1 pipeline, funds runway into Q2 2027

Vivani Medical (VANI) has reported a net loss of $6.4 million for Q2 2026 and $13.2 million for the first half of 2026, with cash and equivalents totaling $19.9 million, which is projected to fund operations into Q2 2027. The company is advancing its …

Form 8K Vivani Medical Inc For: 13 August By Investing.com

This article reports on the filing of a Form 8K by Vivani Medical Inc. on August 13th, as tracked by Investing.com. The brief mention indicates a financial disclosure event for the company, with the stock symbol VANI noted to have experienced a -2.19% change.

Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update

Vivani Medical reported its second-quarter 2026 financial results, highlighting significant progress in its clinical development, including the successful dosing of all participants in its SLIM-1 Phase 1 trial for NPM-139, a semaglutide implant for chronic weight management. The company also announced a non-exclusive agreement …